Isaac (Tzachy) Tal
CEO
Claimed by owner Tamarix Pharma
Former names:
Therapies for Apoptosis-driven Diseases
Tamarix Pharma
About
Tamarix Pharma is an early-stage biotech company focused on developing novel technologies that restore physiological balance in apoptosis-related diseases.
The company's lead assets are VBIT-4 and VBIT-12, small molecules targeting VDAC1 oligomerization. They were deliberately designed to target a key mitochondrial process known as VDAC1 oligomerization. Their unique mechanism of action represents a highly differentiated approach to potentially treating a variety of acute and chronic conditions resulting from apoptotic cell death.
The company's lead assets are VBIT-4 and VBIT-12, small molecules targeting VDAC1 oligomerization. They were deliberately designed to target a key mitochondrial process known as VDAC1 oligomerization. Their unique mechanism of action represents a highly differentiated approach to potentially treating a variety of acute and chronic conditions resulting from apoptotic cell death.
Primary Sector
Life Sciences & HealthTech
Products
VBIT-4, VBIT-12
Geographic markets
-
Funding
Total Funding
Undisclosed
Last Funding
Undisclosed
Funding Stage
Total Rounds
1
Investors
4
News
(0)The Team
(2)
I(T
CZ
Corinne Zollmann
SVP CMC
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
Seed
Undisclosed
Jan 2021
4 Investors
Undisclosed
Media gallery
(0)Locations
Israel
Professor Rakakh Street 1, Jerusalem, Israel
Locations
Israel
Professor Rakakh Street 1, Jerusalem, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,